Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Principal Accounting Officer | April 24, 2026 | April 28, 2026 |
| MiNK Therapeutics, Inc.INKT · Entity 52 | Principal Accounting Officer | March 13, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date April 24, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2036-04-24 | Direct | 5,000 |
Reported balance
After 2026-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 5,000 · Balance 5,000 F1: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2036-04-24 | Direct | 17,619 |
Reported balance
After 2026-04-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-24 · Grant · Acquired 17,619 · Balance 17,619 F2: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.
F2: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.
MiNK Therapeutics, Inc.
Report date March 13, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40 |
Reported balance
Holding disclosure · report date 2026-03-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 40 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2026 Filed Apr 28, 2026 20:15 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option · Derivative | 17,619 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001193125-26-187080 · ownership.xml · derivative · entry 2 Charette Austin · CIK 0002105444 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,619 Underlying: Common Stock · 17,619 shares Expires 2036-04-24 F2 · derivative.exercise_date: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 20:15 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option · Derivative | 5,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001193125-26-187080 · ownership.xml · derivative · entry 1 Charette Austin · CIK 0002105444 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-04-24 F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.